Skip to content
Weight Management

Tratamentos de Weight Management

Consulte os tratamentos de weight management disponíveis. Todos incluem revisão por médico independente da UE, medicação genuína de farmácias licenciadas e entrega expresso discreta.

2026-04-11 Tratamentos

Interested in Weight Management?

Complete a confidential health assessment reviewed by an independent EU-registered doctor.

Start Assessment

Weight management tratamentos in Europe

Excess weight and obesity represent one of the most significant public health challenges across the European Union. According to the Organização Mundial da Saúde, more than half of adults in the WHO European Region are overweight, and approximately 23% live with obesity. The health consequences extend well beyond aesthetics: obesity is a chronic condition associated with type 2 diabetes, cardiovascular disease, hypertension, sleep apnoea, and certain cancers.

For many people, lifestyle interventions — dietary changes and increased physical activity — are the foundation of weight management. However, clinical evidence consistently shows that for individuals with a BMI of 30 or above, or 27 or above with weight-related health conditions, receita médica medications can provide meaningful additional benefit when used alongside lifestyle modifications.

The past decade has seen a significant advancement in the pharmacological options available for weight management in Europe. The approval of GLP-1 receptor agonists by the Agência Europeia de Medicamentos (EMA) has given médicos access to medications with demonstrated efficacy: clinical trials published in the New England Journal of Medicine show that semaglutide (the active ingredient in both Ozempic and Wegovy) produced an average weight reduction of approximately 15% of body weight over 68 weeks in adults with obesity. This represents a step-change compared to older weight management medications.

It is important to understand that receita médica weight management medications are not a substitute for lifestyle changes, and they are not appropriate for everyone. All prescribing decisions must be made by a qualified, independent médico based on a thorough assessment of each individual’s clinical circumstances.

Available tratamentos

The following receita médica medications are available for weight management through EU-registered médicos. This comparison is provided for informational purposes only. A médico will assess which medication, if any, is appropriate for your individual situation.

MedicationActive IngredientFormTypical Dose RangeEMA-Approved Indication
OzempicSemaglutideWeekly injeção0.5 mg–2 mg/weekType 2 diabetes (also used off-label for weight management)
WegovySemaglutideWeekly injeçãoUp to 2.4 mg/weekChronic weight management
SaxendaLiraglutideDaily injeçãoUp to 3 mg/dayChronic weight management

Key distinctions:

  • Ozempic vs Wegovy: Both contain semaglutide, a GLP-1 receptor agonist. Ozempic carries EMA approval for type 2 diabetes management; Wegovy is the formulation approved specifically for chronic weight management at a higher maximum dose. Clinical data indicates that the higher semaglutide dose in Wegovy produces greater average weight loss.
  • Saxenda: Contains liraglutide, a different GLP-1 receptor agonist requiring daily rather than weekly injeçãos. Clinical head-to-head evidence suggests semaglutide achieves greater mean weight reduction than liraglutide over comparable tratamento periods.
  • Starting price: Prices vary by country, farmácia, and dosagem. Use the links above to see indicative starting prices for each medication through Prescrivia’s platform.

Como obter weight management tratamento online

Prescrivia operates as a technology intermediary. We do not prescribe medications, employ médicos, or sell medicamentos. Our platform connects pacientes across Europe with independent EU-registered médicos and licensed pharmacies.

The process:

  1. Complete uma avaliação de saúde — Answer a structured set of medical questions covering your health history, current medications, BMI, and weight management goals. The assessment is designed to give the reviewing médico a thorough clinical picture.

  2. Independent médico review — An independent EU-registered médico reviews your assessment. If a receita médica medication is clinically appropriate for you, the médico may issue a receita médica. If it is not appropriate — due to contraindications, insufficient clinical indication, or other factors — the médico will explain the reasoning.

  3. Dispensa na farmácia — If a receita médica is issued, it is passed to a licensed EU farmácia partner. The farmácia dispenses the medication and arranges delivery directly to your address.

Important: A Prescrivia não garante that a receita médica will be issued. Prescribing decisions are made entirely by independent medical professionals. All medications are medicamento sujeito a receita médicas (POMs) in estados-membros da UE and require a valid receita médica from a licensed médico.

How we compare

Through PrescriviaIn-person GP appointment
Availability24/7 online assessmentSubject to appointment availability
Wait timeAssessment reviewed within hoursDays to weeks depending on location
Travel requiredNoYes
Prescribing decisionMade by independent EU-registered médicoMade by your GP
Ongoing monitoringSupported via follow-up assessmentsManaged by your GP
CostTransparent pricing displayed upfrontVaries by country and healthcare system

Note: For pacientes with complex medical histories, multiple comorbidities, or conditions requiring close clinical monitoring, an in-person consultation with a GP or specialist may be more appropriate. Prescrivia’s platform is designed for adults who meet the clinical criteria for receita médica weight management medications and whose health profile is suitable for remote assessment.

Fontes

Medical information on this page is based on the following sources:

  • Agência Europeia de Medicamentos (EMA). Wegovy (semaglutide) — Summary of Product Characteristics. Available at: ema.europa.eu
  • Agência Europeia de Medicamentos (EMA). Saxenda (liraglutide) — Summary of Product Characteristics. Available at: ema.europa.eu
  • Organização Mundial da Saúde (WHO). Obesity and overweight in the WHO European Region — Fact sheet. euro.who.int
  • Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.

This content is reviewed periodically to reflect updated clinical guidance. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.

Frequently asked questions

Posso obter weight loss medication online na Europa?
Yes, you can access weight management medications through online intermediary platforms that connect you with independent EU-registered médicos. A médico will assess whether tratamento is clinically appropriate based on your health profile.
Do I need a BMI of 30 to qualify for weight loss medication?
Eligibility depends on the specific medication and clinical guidelines. Generally, GLP-1 medications are considered for pacientes with a BMI of 30+ (obese) or 27+ (overweight) with weight-related comorbidities. The prescribing médico makes the final determination.
How much weight can I lose with receita médica weight management medication?
Clinical trials show that GLP-1 receptor agonists like semaglutide can lead to an average weight reduction of 12-15% of body weight over 68 weeks, though individual results vary significantly.
Are weight management medications safe?
EMA-approved weight management medications have undergone extensive clinical trials. Efeitos secundários comuns include gastrointestinal symptoms that typically diminish over time. A qualified médico will assess whether the benefits outweigh the risks for your individual situation.
O que é the difference between Ozempic and Wegovy?
Both contain semaglutide, but Ozempic is approved for type 2 diabetes while Wegovy is specifically approved for weight management at a higher dose (2.4mg vs 2mg). Your médico will determine which is most appropriate.
A Prescrivia é apenas uma plataforma intermediária. Não prestamos serviços médicos, não prescrevemos tratamentos nem dispensamos medicamentos. Todas as decisões médicas são tomadas por médicos independentes registados na UE. Todos os medicamentos são dispensados por farmácias licenciadas na UE. Esta plataforma facilita a ligação entre pacientes e prestadores de cuidados de saúde.

Written by Prescrivia Editorial. Medical information sourced from European Medicines Agency (EMA), World Health Organization (WHO), and published clinical data.

This content is informational only and does not constitute medical advice.

Last updated:

Pronto para começar?

Complete uma avaliação de saúde confidencial em cerca de 3 minutos.